Microbot Medical MBOT Cash and cash equivalents, end of period
Cash and cash equivalents, end of period at other companies
Other financials
Where this comes from
Reported directly by Microbot Medical in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.
The official record: Microbot Medical’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Microbot Medical's cash and cash equivalents, end of period.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Microbot Medical's cash and cash equivalents, end of period?
- Microbot Medical (MBOT) reported cash and cash equivalents, end of period of $3.92M in Q1 2026.
- How has Microbot Medical's cash and cash equivalents, end of period changed year-over-year?
- Microbot Medical's cash and cash equivalents, end of period increased by 20.0% year-over-year, from $3.27M to $3.92M.
- What is the long-term trend for Microbot Medical's cash and cash equivalents, end of period?
- Over 5 years (2020 to 2025), Microbot Medical's cash and cash equivalents, end of period has grown at a -27.4% compound annual growth rate (CAGR), from $19.73M to $3.97M.